SLS BIO Co., Ltd (KOSDAQ:246250)

SLS BIO Statistics

Total Valuation

SLS BIO has a market cap or net worth of KRW 26.89 billion. The enterprise value is 20.82 billion.

Market Cap	26.89B
Enterprise Value	20.82B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

SLS BIO has 13.66 million shares outstanding. The number of shares has decreased by -15.34% in one year.

Current Share Class	13.66M
Shares Outstanding	13.66M
Shares Change (YoY)	-15.34%
Shares Change (QoQ)	+2.27%
Owned by Insiders (%)	34.28%
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.44
PB Ratio	4.02
P/TBV Ratio	4.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.69
EV / Sales	6.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.40

Financial Position

The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.17.

Current Ratio	2.17
Quick Ratio	1.86
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	-0.25
Interest Coverage	-78.60

Financial Efficiency

Return on equity (ROE) is -59.35% and return on invested capital (ROIC) is -86.29%.

Return on Equity (ROE)	-59.35%
Return on Assets (ROA)	-23.38%
Return on Invested Capital (ROIC)	-86.29%
Return on Capital Employed (ROCE)	-57.38%
Weighted Average Cost of Capital (WACC)	6.95%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.25
Inventory Turnover	34.39

Taxes

Income Tax	-473.79M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.58% in the last 52 weeks. The beta is 0.51, so SLS BIO's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	-15.58%
50-Day Moving Average	1,829.32
200-Day Moving Average	2,434.91
Relative Strength Index (RSI)	48.32
Average Volume (20 Days)	4,356,170

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SLS BIO had revenue of KRW 3.19 billion and -5.64 billion in losses. Loss per share was -382.48.

Revenue	3.19B
Gross Profit	-2.75B
Operating Income	-4.84B
Pretax Income	-6.12B
Net Income	-5.64B
EBITDA	-3.57B
EBIT	-4.84B
Loss Per Share	-382.48

Balance Sheet

The company has 2.27 billion in cash and 1.16 billion in debt, with a net cash position of 1.11 billion or 81.40 per share.

Cash & Cash Equivalents	2.27B
Total Debt	1.16B
Net Cash	1.11B
Net Cash Per Share	81.40
Equity (Book Value)	6.70B
Book Value Per Share	435.13
Working Capital	1.94B

Cash Flow

In the last 12 months, operating cash flow was -3.19 billion and capital expenditures -1.55 billion, giving a free cash flow of -4.74 billion.

Operating Cash Flow	-3.19B
Capital Expenditures	-1.55B
Depreciation & Amortization	1.27B
Net Borrowing	-622.27M
Free Cash Flow	-4.74B
FCF Per Share	-346.83

Margins

Gross margin is -86.35%, with operating and profit margins of -151.75% and -177.10%.

Gross Margin	-86.35%
Operating Margin	-151.75%
Pretax Margin	-191.96%
Profit Margin	-177.10%
EBITDA Margin	-112.02%
EBIT Margin	-151.75%
FCF Margin	n/a

Dividends & Yields

SLS BIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	15.34%
Shareholder Yield	15.34%
Earnings Yield	-20.99%
FCF Yield	-17.61%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 12, 2024. It was a forward split with a ratio of 2.

Last Split Date	Jul 12, 2024
Split Type	Forward
Split Ratio	2

Scores

SLS BIO has an Altman Z-Score of 3.24 and a Piotroski F-Score of 1.

Altman Z-Score	3.24
Piotroski F-Score	1